UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 70

Sortiert nach

Tumor-Associated Macrophage Status in Cancer Treatment

Cancers, 2020-07, Vol.12 (7), p.1987

2020

Volltextzugriff (PDF)

The novel butyrate derivative phenylalanine‐butyramide protects from doxorubicin‐induced cardiotoxicity

European journal of heart failure, 2019-04, Vol.21 (4), p.519-528

2019

Volltextzugriff (PDF)

Mesothelioma-Associated Fibroblasts Modulate the Response of Mesothelioma Patient-Derived Organoids to Chemotherapy via Interleukin-6

International journal of molecular sciences, 2024-05, Vol.25 (10), p.5355

2024

Volltextzugriff (PDF)

Tumour Microenvironment and Immune Evasion in EGFR Addicted NSCLC: Hurdles and Possibilities

Cancers, 2019-09, Vol.11 (10), p.1419

2019

Volltextzugriff (PDF)

Insights into Network of Hot Spots of Aggregation in Nucleophosmin 1

International journal of molecular sciences, 2022-11, Vol.23 (23), p.14704

2022

Volltextzugriff (PDF)

A Comparative Study of the Effects of Platinum (II) Complexes on β-Amyloid Aggregation: Potential Neurodrug Applications

International journal of molecular sciences, 2021-03, Vol.22 (6), p.3015

2021

Volltextzugriff (PDF)

Analysis of phase III clinical trials in metastatic NSCLC to assess the correlation between QoL results and survival outcomes

BMC medicine, 2023-07, Vol.21 (1), p.234-234, Article 234

2023

Volltextzugriff (PDF)

PRMT5 is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancer

Nature communications, 2024-03, Vol.15 (1), p.2287-2287, Article 2287

2024

Volltextzugriff (PDF)

Synthesis and In Vitro Characterization of Selective Cannabinoid CB2 Receptor Agonists: Biological Evaluation against Neuroblastoma Cancer Cells

Molecules (Basel, Switzerland), 2022-05, Vol.27 (9), p.3019

2022

Volltextzugriff (PDF)

Toxicity profile of antibody-drug conjugates in breast cancer: practical considerations

EClinicalMedicine, 2023-08, Vol.62, p.102113-102113, Article 102113

2023

Volltextzugriff (PDF)

Immunological signature of patients with thymic epithelial tumors and Good syndrome

Frontiers in immunology, 2022-08, Vol.13, p.908453-908453

2022

Volltextzugriff (PDF)

Neoadjuvant Treatment in Locally Advanced Pancreatic Cancer (LAPC) Patients with FOLFIRINOX or Gemcitabine NabPaclitaxel: A Single-Center Experience and a Literature Review

Cancers, 2019-07, Vol.11 (7), p.981

2019

Volltextzugriff (PDF)

Cross Talk of Macrophages with Tumor Microenvironment Cells and Modulation of Macrophages in Cancer by Virotherapy

Biomedicines, 2021-09, Vol.9 (10), p.1309

2021

Volltextzugriff (PDF)

Targeting G-quadruplex motifs interferes with differentiation of adipose-derived mesenchymal stem cells

Stem cell research & therapy, 2023-04, Vol.14 (1), p.98-98, Article 98

2023

Volltextzugriff (PDF)

Analysis of Health-Related Quality of Life Reporting in Phase III RCTs of Advanced Genitourinary Tumors

Cancers, 2023-12, Vol.15 (23), p.5703

2023

Volltextzugriff (PDF)

Insight on the Role of Leptin: A Bridge from Obesity to Breast Cancer

Biomolecules (Basel, Switzerland), 2022-09, Vol.12 (10), p.1394

2022

Volltextzugriff (PDF)

Combination of dl922-947 Oncolytic Adenovirus and G-Quadruplex Binders Uncovers Improved Antitumor Activity in Breast Cancer

Cells (Basel, Switzerland), 2022-08, Vol.11 (16), p.2482

2022

Volltextzugriff (PDF)

FOLFIRINOX after first-line gemcitabine-based chemotherapy in advanced pancreatic cancer: a retrospective comparison with FOLFOX and FOLFIRI schedules

Therapeutic advances in medical oncology, 2020, Vol.12, p.1758835920947970-1758835920947970

2020

Volltextzugriff (PDF)

Use of FOLFIRINOX or Nab-Paclitaxel Plus Gemcitabine for the Treatment of Locally Advanced Pancreatic Adenocarcinoma: A Single Institution Observational Study

Cancers, 2021-09, Vol.13 (19), p.4939

2021

Volltextzugriff (PDF)

Pak1 pathway hyper-activation mediates resistance to endocrine therapy and CDK4/6 inhibitors in ER+ breast cancer

NPJ breast cancer, 2023-05, Vol.9 (1), p.48-48, Article 48

2023

Volltextzugriff (PDF)

Role of FGFR3 in bladder cancer: Treatment landscape and future challenges

Cancer treatment reviews, 2023-04, Vol.115, p.102530-102530, Article 102530

2023

Volltextzugriff (PDF)

History of how viruses can fight cancer: From the miraculous healings to the approval of oncolytic viruses

Biochimie, 2023-03, Vol.206, p.89-92

2023

Volltextzugriff (PDF)

Metal-Complexes Bearing Releasable CO Differently Modulate Amyloid Aggregation

Inorganic chemistry, 2023-07, Vol.62 (26), p.10470-10480

2023

Volltextzugriff (PDF)

EGFR and HER2 hyper-activation mediates resistance to endocrine therapy and CDK4/6 inhibitors in ER+ breast cancer

Cancer letters, 2024-07, Vol.593, p.216968, Article 216968

2024

Volltextzugriff (PDF)

Mechanisms of resistance to mTOR inhibitors

Critical reviews in oncology/hematology, 2020-03, Vol.147, p.102886-102886, Article 102886

2020

Volltextzugriff (PDF)

1 – 25 von 70

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(68)
Mit Volltextzugriff
(68)

Publikationsform

Artikel
(70)

Sprache

Englisch
(70)
Japanisch
(7)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Tumor-Associated Macrophage Status in Cancer Treatment

The novel butyrate derivative phenylalanine‐butyramide protects from doxorubicin‐induced cardiotoxicity

Mesothelioma-Associated Fibroblasts Modulate the Response of Mesothelioma Patient-Derived Organoids to Chemotherapy via Interleukin-6

Tumour Microenvironment and Immune Evasion in EGFR Addicted NSCLC: Hurdles and Possibilities

Insights into Network of Hot Spots of Aggregation in Nucleophosmin 1

A Comparative Study of the Effects of Platinum (II) Complexes on β-Amyloid Aggregation: Potential Neurodrug Applications

Analysis of phase III clinical trials in metastatic NSCLC to assess the correlation between QoL results and survival outcomes

PRMT5 is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancer

Synthesis and In Vitro Characterization of Selective Cannabinoid CB2 Receptor Agonists: Biological Evaluation against Neuroblastoma Cancer Cells

Toxicity profile of antibody-drug conjugates in breast cancer: practical considerations

Immunological signature of patients with thymic epithelial tumors and Good syndrome

Neoadjuvant Treatment in Locally Advanced Pancreatic Cancer (LAPC) Patients with FOLFIRINOX or Gemcitabine NabPaclitaxel: A Single-Center Experience and a Literature Review

Cross Talk of Macrophages with Tumor Microenvironment Cells and Modulation of Macrophages in Cancer by Virotherapy

Targeting G-quadruplex motifs interferes with differentiation of adipose-derived mesenchymal stem cells

Analysis of Health-Related Quality of Life Reporting in Phase III RCTs of Advanced Genitourinary Tumors

Insight on the Role of Leptin: A Bridge from Obesity to Breast Cancer

Combination of dl922-947 Oncolytic Adenovirus and G-Quadruplex Binders Uncovers Improved Antitumor Activity in Breast Cancer

FOLFIRINOX after first-line gemcitabine-based chemotherapy in advanced pancreatic cancer: a retrospective comparison with FOLFOX and FOLFIRI schedules

Use of FOLFIRINOX or Nab-Paclitaxel Plus Gemcitabine for the Treatment of Locally Advanced Pancreatic Adenocarcinoma: A Single Institution Observational Study

Pak1 pathway hyper-activation mediates resistance to endocrine therapy and CDK4/6 inhibitors in ER+ breast cancer

Role of FGFR3 in bladder cancer: Treatment landscape and future challenges

History of how viruses can fight cancer: From the miraculous healings to the approval of oncolytic viruses

Metal-Complexes Bearing Releasable CO Differently Modulate Amyloid Aggregation

EGFR and HER2 hyper-activation mediates resistance to endocrine therapy and CDK4/6 inhibitors in ER+ breast cancer

Mechanisms of resistance to mTOR inhibitors

Suchergebnisse filtern